A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
This single-arm, open-label, multi-center study will enroll 60 patients from approximately 20 centers. All patients who meet study criteria and are currently taking, beginning or resuming treatment with Deferasirox will be allowed. The study will begin with a one month run-in phase, where all patients will be instructed to take Deferasirox according to their physician's current prescribing information.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : deferasirox:
Phase: Phase 4
Ages Eligible For Study: